Nalaganje...
Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
Imatinib, a breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myelogenous leukemia (CML). However, development of multidrug resistance (MDR) limits the use of imatinib. In the present study, we aimed to investig...
Shranjeno v:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Sun Yat-sen University Cancer Center
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3777469/ https://ncbi.nlm.nih.gov/pubmed/22098951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.011.10327 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|